EBR Systems, Inc. · ASX:EBR
EBR Systems — Q2 2026 Earnings Presentation
9 slides from EBR Systems's earnings presentation, Jul 31, 2026
Slide 1: EBR Investor Webinar: Preliminary Q2 2026 Results
For personal use only EBR Investor Webinar: Preliminary Q2 2026 Results Discussion Regarding Reported Complications 31 July 2026
Slide 2: Disclaimer
Disclaimer The material contained in this document is a presentation of general information about the may differ materially from what is expressed in this presentation. activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentati
Slide 3: Building Momentum in the WiSE System
Building Momentum in the WiSE System EBR has achieved several key milestones and is well positioned to continue to capitalise on its existing momentum to drive further growth. Limited market release will continue through 2026 and into 2027, with a focus on laying groundwork for broader sales coverag
Slide 4: Preliminary Q2 2026 Results
For personal use only Preliminary Q2 2026 Results
Slide 5: Q2'26 Key Milestones
Q2’26 Key Milestones • Partially completed a fully underwritten A$150m capital raise For personal use only − Final $A35m underwritten tranche expected to be completed by 24 Aug 26 − Support pathway to cashflow breakeven • CMS initiated their National Coverage Determination process for WiSE − Provide
Slide 6: Q2'26 Commercial Progress
Q2’26 Commercial Progress Limited market release starts with trained salespeople, who then engage physicians, followed by hospital contracting negotiations, leading to treated patients and revenue For personal use only Physician Engagement → Site Negotiation and Contracting → Initial Implants → Pati
Slide 7: Recent Online Report of Complications
For personal use only Recent Online Report of Complications
Slide 8: EBR Internal Investigation Completed
EBR Internal Investigation Completed • MedSun report was not written by FDA, but was the hospital’s report to For personal use only the FDA • EBR has completed its internal investigation without receiving any official information from the hospital and is submitting that to FDA within the required re
Slide 9: Contact
For personal use only Contact: Company Investors Andrew Shute Gabriella Hold Chief Corporate Development Officer The Capital Network P: +44 7730 691421 P: +61 2 8999 3699 E: [email protected] E: [email protected] www.ebrsystemsinc.com 9